文献速递甲状腺疾病

仑伐替尼治疗甲状腺癌意大利扩展可及项目的安全性与生活质量数据

Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
PubMed 文献 · Thyroid · 2020-10-22

该研究纳入39例放射性碘难治性分化型甲状腺癌(RR-DTC)患者,在仑伐替尼治疗6个月内记录并分级不良事件(AE),并与SELECT和TUTHYREF研究的安全性数据比较,同时用EORTC QLQ-C30和疼痛VAS评估生活质量。最常见AE为高血压(80.5%)、乏力(58.3%)、腹泻(36.1%)等,最常见3/4级AE为高血压(25%);与既往研究相比,腹泻、恶心、蛋白尿和体重减轻发生率显著更低。生活质量在治疗前、治疗中及随访结束(开始治疗后6个月)无统计学显著差异,但整体健康状况及情绪、认知状态略有改善,而躯体角色和社会功能略有恶化。

要点

  • 仑伐替尼治疗RR-DTC最常见AE为高血压(80.5%)和乏力(58.3%),3/4级AE以高血压(25%)为主。
  • 与SELECT和TUTHYREF研究相比,腹泻、恶心、蛋白尿和体重减轻发生率显著更低。
  • 6个月内生活质量无统计学显著变化,整体健康状况和情绪认知略有改善,乏力、厌食/体重减轻和口腔炎仍是主要管理难题。

核心结论

  • 仑伐替尼在RR-DTC患者中的安全性特征与既往报道相似,但部分AE的患病率和严重程度存在差异。
  • 扩展可及项目显示整体健康状况有改善趋势且疾病相关症状减少,但乏力、厌食/体重减轻和口腔炎仍是临床管理的主要问题。

研究设计与样本

  • 意大利扩展可及项目(EAP)研究,纳入39例RR-DTC患者,记录并分级仑伐替尼治疗6个月内的所有AE。
  • 安全性数据与SELECT和TUTHYREF研究比较,生活质量采用EORTC QLQ-C30和疼痛VAS评估。

主要发现

  • 39例RR-DTC患者中最常见AE为高血压(80.5%)、乏力(58.3%)、腹泻(36.1%)、口腔炎(33.3%)、手足综合征(33.3%)和体重减轻(30.5%)。
  • 最常见的3/4级AE为高血压(25%)。
  • 与SELECT和TUTHYREF研究相比,本组患者腹泻、恶心、蛋白尿和体重减轻的发生率显著更低。
  • 生活质量在治疗前、治疗中及随访结束(开始治疗后6个月)无统计学显著差异。
  • 6个月内整体健康状况及情绪和认知状态略有改善,躯体角色和社会功能略有恶化;疼痛、呼吸困难、失眠和便秘趋向改善,乏力、恶心呕吐、食欲丧失和腹泻恶化;疼痛VAS显示整体疼痛水平降低。

临床怎么用

  • 临床管理RR-DTC患者接受仑伐替尼治疗时,应重点监测和管理高血压、乏力、腹泻、口腔炎、手足综合征及体重减轻等AE。
  • 尽管生活质量总体无显著恶化,但需关注乏力、厌食/体重减轻和口腔炎对患者的影响,并采取相应支持措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Lenvatinib, a multikinase inhibitor, is for progressive radioiodine-refractory-differentiated thyroid cancer (RR-DTC) patients. However, there are a lot of drug-related adverse events (AEs) that can affect the quality of life (QoL) of patients. The aims of this study were (a) to evaluate, and compared with other series, the safety of lenvatinib used in RR-DTC patients enrolled in an Italian expanded access program (EAP), and (b) to evaluate their QoL during treatment with lenvatinib. Methods: To evaluate the safety, we recorded and graded all AEs during the 6 months of lenvatinib treatment in 39 RR-DTC patients. We compared the safety profile of lenvatinib observed in our patients with that reported in the study of (E7080) levatinib in differentiated cancer of the thyroid (SELECT) and tumeurs thyroidiennes refractaires (TUTHYREF) network studies. Moreover, we evaluated the QoL in our series by using the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 and the pain visual analogue scale (VAS). Results: The most frequent AEs among our 39 RR-DTC patients were hypertension (80.5%), fatigue (58.3%), diarrhea (36.1%), stomatitis (33.3%), hand/foot syndrome (33.3%), and weight loss (30.5%). The most prevalent grade 3/4 AE was hypertension (25%). When compared with previous studies (i.e., SELECT and TUTHYREF), a significantly lower percentage of our patients experienced diarrhea, nausea, proteinuria, and weight loss. No statistically significant differences in the QoL of our patients evaluated before, during, and at the end of follow-up (6 months after starting the therapy) were found. However, a slight improvement of the general health and emotional and cognitive status associated with a slightly worsening of physical role and social functioning was observed during these 6 months. Pain, dyspnea, insomnia, and constipation moved toward better values, while fatigue, nausea and vomiting, appetite loss, and diarrhea worsened. By comparing the pain VAS, an overall reduction of the level of pain was found. Conclusions: The safety profile of the drug was similar to that already reported with some differences in the prevalence and severity of the AEs. Regarding the QoL, the EAP showed a trend of improvement of the global health status and a reduction of symptoms correlated to the disease. The clinical impact of fatigue, anorexia/weight loss and stomatitis, mainly due to the drug itself, continues to represent the major issue in the management of these patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Giani C, Valerio L, Bongiovanni A, et al. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. Thyroid. 2020. PMID: 32907501. doi:10.1089/thy.2020.0276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。